5AX3
Crystal structure of ERK2 complexed with allosteric and ATP-competitive inhibitors.
Summary for 5AX3
| Entry DOI | 10.2210/pdb5ax3/pdb |
| Descriptor | Mitogen-activated protein kinase 1, allosteric and ATP-competitive inhibitor, (2R,3R,4S,5R)-2-(4-AMINO-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL (3 entities in total) |
| Functional Keywords | ternary complex, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| Biological source | Homo sapiens (Human) More |
| Total number of polymer chains | 2 |
| Total formula weight | 44115.40 |
| Authors | Kinoshita, T.,Sugiyama, H.,Mori, Y.,Takahashi, N.,Tomonaga, A. (deposition date: 2015-07-14, release date: 2016-02-10, Last modification date: 2023-11-08) |
| Primary citation | Kinoshita, T.,Sugiyama, H.,Mori, Y.,Takahashi, N.,Tomonaga, A. Identification of allosteric ERK2 inhibitors through in silico biased screening and competitive binding assay Bioorg.Med.Chem.Lett., 26:955-958, 2016 Cited by PubMed Abstract: Extracellular signal-regulated kinase 2 (ERK2) is a drug target for type 2 diabetes mellitus. A peptide-type ERK2 inhibitor (PEP) was discovered in the previous study through the knowledge-based method and showed physiological effects on the db/db mice model of type 2 diabetes. Here, the crystal structure showed that PEP bound to the allosteric site without the interruption of the ATP competitive inhibitor binding to ERK2. An in silico biased-screening using the focused library rendered three compounds with inhibitory activity of IC50 <100 μM. Among them, two compounds revealed the concentration-dependent competition with PEP and could be lead compounds for antidiabetic medicine. PubMed: 26733474DOI: 10.1016/j.bmcl.2015.12.056 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.984 Å) |
Structure validation
Download full validation report
